Mr Hogg has been an Executive Director and the Chief Executive Officer since 2006. He is also a member of the Technical Committee of the Company. He joined Hutchison China in 2000 and has since led all aspects of the creation, implementation and management of the Company’s strategy, business and listing. This includes the creation of the Company’s start-up businesses and the acquisition and operational integration of assets that led to the formation of the Company’s China joint ventures.
Prior to joining Hutchison China, Mr Hogg spent ten years with P&G starting in the United States in Finance and then Brand Management in the Laundry and Cleaning Products Division. Mr Hogg then moved to China to manage P&G’s detergent business followed by a move to Brussels to run P&G’s global bleach business. Mr Hogg received a Bachelor’s degree in Civil Engineering from the University of Edinburgh and an MBA from the University of Tennessee.
Mr Cheng has been an Executive Director since 2011 and the Chief Financial Officer of the Company since 2008. He is also a director of Hutchison MediPharma (Hong Kong) Limited, Sen Medicine Company Limited, Hutchison MediPharma Limited, Hutchison MediPharma (Suzhou) Limited and Hutchison MediPharma (Yulin) Limited. He was a director of Hutchison Healthcare Limited during 2009.
Prior to joining the Company, Mr Cheng was Vice President, Finance of Bristol Myers Squibb in China and was a director of Sino-American Shanghai Squibb Pharmaceuticals Ltd. and Bristol-Myers Squibb (China) Investment Co. Ltd. in Shanghai between late 2006 and 2008.
Mr Cheng started his career as an auditor with Price Waterhouse (currently PricewaterhouseCoopers) in Australia and then KPMG in Beijing before spending eight years with Nestlé China where he was in charge of a number of finance and control functions in various operations. Mr Cheng received a Bachelor of Economics, Accounting Major from the University of Adelaide and is a member of the Institute of Chartered Accountants in Australia.
Dr Su has been an Executive Director since March 27, 2017. He is also a member of the Technical Committee of the Company. He has been the Executive Vice President and Chief Scientific Officer of the Company since 2012. Dr Su has headed all drug discovery and research since he joined the Company, including master-minding the Company’s scientific strategy, being a key leader of the Innovation Platform, and responsible for the discovery of each and every small molecule drug candidate in the Company’s product pipeline. Prior to joining the Company in 2005, Dr Su spent 15 years with the U.S. Research and Development Department of Pfizer, Inc. with his last position as director of the Medicinal Chemistry Department.
In March 2017, Dr Su was granted the prestigious award by the China Pharmaceutical Innovation and Research Development Association (PhIRDA) as one of the Most Influential Drug R&D Leaders in China.
Dr Su received a Bachelor of Science degree in Chemistry from Fudan University in Shanghai. He completed a PhD and Post-doctoral Fellowship in Chemistry at Harvard University under the guidance of Nobel Laureate Professor E. J. Corey.
Dr. Wu heads all non-clinical development at the company, focusing on the CMC development and manufacturing of the Company’s pipeline. The Pharmaceutical Sciences department is responsible for process research, API & drug product manufacture, analytical R&D, quality control, supply chain management, CMC regulatory affairs, pilot plant development, and managing third party contractors. Dr Wu has over 25 years of experience in drug discovery and development.
Prior to joining HMP in 2008, Dr Wu held several leadership positions, including Senior Director of Pharmaceutical Sciences at Phenomix, a California biotech company; Director of Pharmaceutical Development at Pfizer Global R&D in San Diego (formerly Agouron); and group leader at Roche in Palo Alto. Dr. Wu has led many teams and advanced numerous candidates through different phases of clinical development and commercialization, such as the blockbuster anti-cancer drug Sutent.
Dr. Wu received a Ph. D. degree from Hong Kong University, and an MBA degree from the University of California at Irvine. He is the past Chairman and President of the Board of the Sino-American Biotechnology and Pharmaceutical Association. He received a Dean’s Scholar Award from the University of California at Irvine, a Leadership Award from the Sino-American Biotechnology and Pharmaceutical Association, and an American Heart Association Fellowship.
Mr. Lee focuses on HMP’s strategic management, corporate operations, investor relations and supporting its numerous R&D alliances. This includes leading or assisting with the project management of certain clinical programmes, coordination of R&D leadership, and R&D financial management.
Prior to joining the company in 2009, Mr. Lee was with Credit Suisse in the United States and Europe, where he was involved in the execution and origination of mergers, acquisitions, public and private financings, and corporate strategy for pharmaceutical, life science and healthcare companies such as AstraZeneca, Bristol-Myers Squibb, Genzyme and Syngenta, amongst others.
Mr Lee received his Bachelor of Engineering in Biochemical Engineering with First Class Honours from University College London, where he was awarded a Dean’s Commendation. He also received a Master of Business Administration from the Massachusetts Institute of Technology, Sloan School of Management.
Dr. Wang heads all alliance management and business development for the company. She has been instrumental in engaging with, negotiating, executing and very actively liaising with all our development partners, including AstraZeneca, Nestlé Health Science, and Eli Lilly.
Prior to joining HMP in 2010, Dr. Wang spent 16 years with Eli Lilly and was the Head for Asian Biology Research, responsible for establishing and managing research collaborations in China and Pan-Asia. Dr. Wang has broad drug discovery and development experience spanning several therapeutic areas including infectious diseases, inflammation and oncology. She was a co-inventor for several drug candidates including the blockbuster drug INCIVEK (telaprevir, LY570310) launched in 2011 for treatment of HCV infection.
Dr. Wang has numerous patents, published more than 50 peer-reviewed articles and has given dozens of seminars and plenary lectures. She received her Ph.D. in Biology from Purdue University, USA.
Dr. Hua leads and manages the clinical organization and oversees seven development programmes that are being developed in different indications. Under his leadership, the clinical development pipeline has grown from six to nearly 20 clinical trials globally. These include the recent initiation of the Company’s first Phase III trial in China and a US IND in oncology.
Prior to joining the company in 2014 with over 16 years of global new drug development and registration experience, Dr. Hua had worked in Global Clinical Development as Senior Director and Medical Director at Celgene and Novartis, respectively. He led Phase II and III registration trials in oncology, hematology, osteoarthritis, osteoporosis, and infectious disease. As clinical lead, Dr. Hua contributed to the regulatory approval and life-cycle management for Reclast/Aclasta, Prexige, Zometa, Femara, Proleukin and Cardioxane in the US and EU. More recently, at Celgene he led several teams for Revlimid and Pomalyst global development in multiple myeloma, and successfully obtained Revlimid regulatory approval in multiple myeloma in China.
Dr. Hua received a Bachelor’s of Medicine from Fudan University Shanghai Medical College, and a Master’s degree in epidemiology from McGill University in Canada.
Dr. Zhou joined Shanghai Hutchison Pharmaceuticals in 2001.
Prior to this, Dr. Zhou worked for Sanofi Synthélabo for over ten years rising from a Sales Representative to National Sales Director for China. Dr. Zhou holds an MBA from China Europe International Business School (CEIBS) and a Master's degree in Medicine from Xian Medical University, China.
Mr. Chen holds and has held several key senior management roles at Chi-Med, spearheading many of our businesses within our Commercial Platform. When he initially joined Chi-Med he was the Deputy General Manager of Hutchison Baiyunshan, overseeing the manufacture, marketing and distribution of our proprietary OTC drug products. In 2012, he assumed the parallel role of General Manager of Hutchison Healthcare, which focuses on health supplements. In 2014 he stepped down from Hutchison Baiyunshan to become the General Manager of the newly-formed Hutchison Sinopharm business, focusing on providing marketing, distribution and logistics services for prescription drugs manufactured by third parties.
Prior to joining Chi-Med in 2011, Mr. Chen spent twelve years with Bristol-Myers Squibb starting from a Product Manager and becoming its National Sales & Marketing Director in China.
Mr. Chen received a Bachelor's degree in Medicine from Nanjing Medical University, China and an EMBA from Cheung Kong Graduate School of Business.
Mr Walter leads the strategy and management of the Company’s Consumer Products Division, focusing on Health & Beauty products in Asia.
Prior to joining in 2009, Mr Walter spent seven years with the Henkel Group in Germany managing a global Hair Care portfolio with responsibilities to grow sales and profitability through marketing and innovation. Before that he held legal and corporate functions within Henkel dealing with intellectual property, licensing and M&A. Mr Walter started his career as a Corporate and IP lawyer with Arthur Andersen in Germany
Mr Walter holds a law degree from the University of Cologne in Germany and an MBA from Kellogg Northwestern School of Management & WHU, USA. He is also a member of the Bar in Dusseldorf, Germany.
Mr. Leung has spent two decades in investment projects in China, across different places and industries. At Chi-Med he has been involved in structuring and managing direct investment projects, particularly the Hutchison Baiyunshan joint venture. He was one of the leading team members in its establishment and has provided continuous support for its operations, including most recently as its Executive Deputy General Manager.
Prior to joining Hutchison China in 2000, Mr. Leung spent seven years with Hopewell Holdings Limited, focusing on investing, building and operating infrastructure projects in China, including toll roads and power plants. Michael gained extensive China experience through the daily operation of these projects and successfully helped these sino-foreign joint ventures to gain access to funding from foreign banks and overseas investors.
Mr. Leung holds a First Class Honours degree in Business Administration from Simon Fraser University, Canada and received his MBA from the University of British Columbia, Canada.
Mr Nixon has been Group General Counsel of the Company since May 2015 and has worked with the Company since 2006.
Prior to joining the Company, Mr Nixon was Group Senior Legal Counsel for Hutchison Whampoa in both Hong Kong and London and prior to that Senior Legal Counsel for Three UK the mobile phone operator. Mr Nixon has been with the CK Hutchison Group since 2001.
Mr Nixon received an LL.B (Hons) from Middlesex University and is a qualified solicitor in England & Wales with over 20 years of experience.